跳至主要内容
临床试验/NCT07199348
NCT07199348进行中(未招募)不适用

A Safety and Performance Study of the Use of EmboBio for the Intra-arterial Treatment of Abdominopelvic Bleeding: EMBOBIO-1

Embobio Medical1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2025年10月8日最近更新:
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
45
试验地点
1
主要终点
Rate of Serious Adverse Device Effects (SADE)

研究概览

简要总结

This research conducted by EMBOBIO SAS is intended for patients with bleeding or at risk of bleeding in the abdominal-pelvic region requiring embolization.

The EmboBio device (embolization implant) is a Class IIb medical device that is not CE marked (meaning that it is not yet commercially available on the European market).

The objective of the study is to demonstrate the safety and performance of the EmboBio medical embolization device in humans in order to obtain CE marking, the European authorization required for the commercialization of medical devices.

Safety will be assessed by collecting data on events that may be related to the device, and the device will be considered effective if the target arteries are completely occluded (blocked) at the end of the operation.

The plan is to include 45 patients (men and women aged 18 or over who have given their consent to participate in the study) requiring embolization in the abdominal-pelvic region in French hospitals over a period of 12 months. The patient's full participation is requested for a period of approximately 6 months.

详细描述

Abdominopelvic bleeding may occur in different and various circumstances, in a spontaneous way, after a trauma, in a neoplasic context, after a visceral aneurysm's rupture, during or after a surgical treatment. They require fast and effective treatment, as they can be rapidly life-threatening, and that's where embolization steps in.

Embolization is a recent interventional radiology technique whose objective is the occlusion of arterial or venous vessels. Unlike so-called conventional surgical techniques, it is a minimally invasive treatment consisting in endovascular navigation using catheters and microcatheters to reach target vessels where the embolic agent is delivered. The choice of the embolic agent is guided by the indication of the procedure as well as the embolization site. Available permanent embolic agents include calibrated microparticles, metallic implants (coils, plugs) and bioglue. Although the ideal embolic agent does not exist, the choice of material remains a fundamental step in embolization procedures, and the development of new agents is an important avenue of research.

The choice of the embolic agent for bleeding control is based on the site of bleeding, the size of the artery, how fast the bleeding can be controlled but also the time required for embolic agent preparation, its price and the physician's preference. In this indication, the most often used permanent embolic agents are coils. Known adverse device effects of coils are risks of migration, non-target embolization, infection and damage to the wall vessels.

With the urgency of climate change and the demand for natural products in reaction to the overconsumption of chemicals for decades, both food and health industries have experienced a very strong demand for products with a biological process, both respectful of the environment in its design, and of the organism in its distribution. In this context, it seems appealing and important to develop new agents designed from new materials. Indeed, the use of organic materials is a game-changer that is both innovative and promising. More than these aspects, the development of organic embolic material seems necessary to improve the biocompatibility of implantable medical devices with the organism.

To conclude, the best embolic agent for abdominopelvic bleeding should provide a fast and effective long-term occlusion of the bleeding arteries, be safe, prepared speedily, easy to use, cheap and ecofriendly.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years
  • Patient presenting with an arterial abdominopelvic bleeding or risk of bleeding requiring embolization with a permanent embolic agent, i.e. abdominal solid organs hemorrhage including angiomyolipoma, visceral aneurysms and pseudoaneurysms actively bleeding or at risk of bleeding (upper or lower gastrointestinal arteries), pelvic hemorrhage, postpartum hemorrhage in case of active leakage visualized by contrast media extravasation, soft tissue hemorrhage
  • Patient having provided a written informed consent

排除标准

  • Known hypersensitivity to Agar-Agar
  • Known hypersensitivity to iodinated contrast media
  • Patient unable or unwilling to provide a written informed consent
  • Patient unable to provide informed consent due to his clinical condition
  • Patient participating in another interventional study
  • Patient implanted with Embobio device at a previous operating time
  • Vulnerable, pregnant, and breastfeeding population
  • Patient unwilling or unable to follow the study schedule
  • Patients unable to receive prior information on the clinical investigation due to the urgency of the situation
  • Target arteries diameter > 2 mm
  • Vascular anatomy preventing proper placement of the catheter.
  • Arteriovenous shunts with a high flow rate or a diameter greater than 2 mm

研究组 & 干预措施

Embobio

Experimental

Patient implanted with Embobio

干预措施: Embobio (Device)

结局指标

主要结局

Rate of Serious Adverse Device Effects (SADE)

时间窗: 24 hours

The primary endpoint of the pilot stage is the rate of SADE (serious adverse events, probably or certainly related to investigational device deficiencies) within 24 hours.

Rate of technical success

时间窗: At the end of the procedure

The primary performance endpoint is the technical success defined by the successful achievement of embolization of the target artery/arteries, and the absence of extravasation of contrast of target artery/arteries after arterial embolization at the end of the procedure.

Description of procedural data : dosimetry

时间窗: At the end of the procedure

Dosimetry data during the procedure

Description of procedural data : quantity of Embobio

时间窗: At the end of the procedure

Quantity of Embobio used for embolization

Description of procedural data : time to bleeding control

时间窗: At the end of the procedure

Time needed to control the bleeding

Description of procedural data : procedure duration

时间窗: At the end of the procedure

Total duration of the procedure

次要结局

  • Rate of adverse events and adverse device effects(1 week)
  • Rate of immediate clinical success(At the end of the procedure)
  • Rate of clinical success(7 days)
  • Mortality rate(7 days)
  • Name and number of the potentiel other devices used to achieve occlusion(At the end of the procedure)
  • Interventional Radiologist's satisfaction questionnaire(At the end of the procedure)

研究者

发起方
Embobio Medical
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验